* GeoVax Labs Inc reported a quarterly adjusted loss of $13.60 per share for the quarter ended in December, lower than the same quarter last year, when the company reported EPS of $-3.00. The mean expectation of four analysts for the quarter was for a loss of $2.78 per share. Wall Street expected results to range from $-5.10 to 7 cents per share.
* Reported revenue was zero; analysts expected zero.
* GeoVax Labs Inc's reported EPS for the quarter was a loss of $13.60.
* The company reported a quarterly loss of $7.59 million.
* GeoVax Labs Inc shares had fallen by 52.7% this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 33.9% in the last three months.
* In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for GeoVax Labs Inc is $90.00 This summary was machine generated from LSEG data March 1 at 05:19 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -2.78 -13.60 Missed
Sep. 30 2023 -3.60 -4.80 Missed
Jun. 30 2023 -2.47 -3.30 Missed
Mar. 31 2023 -3.05 -2.25 Beat
Comments